<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo>, the underlying pathophysiological mechanism of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, can not only predict type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> development but also <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, precise <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> measurement in individuals at risk for <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e> would support clinical risk stratification </plain></SENT>
<SENT sid="2" pm="."><plain>However, the gold standard for measuring <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, the hyperinsulinemic clamp test, is too labor intensive to be performed in large clinical studies/settings </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Using plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> concentrations from oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests (OGTTs), we developed the novel "clamp-like index" (CLIX) for insulin sensitivity calculation and compared CLIX to clamp <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rates (GIR) (100-120 min) </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated CLIX in 89 nondiabetic subjects (58 female and 31 male, aged 45 +/- 1 years, BMI 27.5 +/- 0.8 kg/m(2)) who underwent frequently sampled 3-h 75-g OGTTs and 2-h hyperinsulinemic-isoglycemic clamp (40 mU/min per m(2)) tests </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: CLIX, calculated as serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> (x0.85 if male)/(mean AUC(<z:chebi fb="105" ids="17234">glucose</z:chebi>) x mean AUC(C-<z:chebi fb="7" ids="16670">peptide</z:chebi>)) x 6,600, was highly correlated (r = 0.670, P &lt; 10(-12)) with and comparable to clamp GIRs(100-120 min) </plain></SENT>
<SENT sid="6" pm="."><plain>In subgroup analyses, GIRs(100-120 min) were lower (P &lt; 0.005) in type 2 diabetic offspring (6.2 +/- 0.7 mg x min(-1) x kg(-1)) than in sex-, age-, and BMI-matched subjects without a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (8.6 +/- 0.5 mg x min(-1) x kg(-1)), which was also reflected by CLIX (insulin-resistant offspring 6.4 +/- 0.6 vs. those without a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 9.0 +/- 0.5; P &lt; 0.002) </plain></SENT>
<SENT sid="7" pm="."><plain>When compared with <z:mpath ids='MPATH_458'>normal</z:mpath>-weight subjects (GIR 8.8 +/- 0.4 mg x min(-1) x kg(-1); CLIX 9.0 +/- 0.5), both GIRs(100-120 min) and CLIX of <z:mp ids='MP_0001261'>obese</z:mp> (5.2 +/- 0.9 mg x min (-1) x kg(-1); 5.7 +/- 0.9) and morbidly <z:mp ids='MP_0001261'>obese</z:mp> (2.4 +/- 0.4 mg x min (-1) x kg(-1); 3.3 +/- 0.5) humans were lower (each P &lt; 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: CLIX, a novel index obtained from plasma OGTT <z:chebi fb="105" ids="17234">glucose</z:chebi> and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, without inclusion of anthropometrical measures to calculate insulin sensitivity in nondiabetic humans, highly correlates with clamp GIRs and reveals even slight insulin sensitivity alterations over a broad BMI range and is as sensitive as the hyperinsulinemic clamp test </plain></SENT>
</text></document>